Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression-Reference-Cited by-同舟云学术

Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression

Published:2024-03-13 Issue:7 Volume:67 Page:5275-5304
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Chen Zhixiang¹,Wang Mi¹,Wu Dimin¹,Bai Longchuan¹,Xu Tianfeng¹^ORCID,Metwally Hoda¹,Wang Yu¹,McEachern Donna¹,Zhao Lijie¹,Li Ruiting²,Takyi-Williams John²,Wang Meilin²,Wang Lu²,Li Qiuxia²,Wen Bo²,Sun Duxin²^ORCID,Wang Shaomeng¹^ORCID

Affiliation:

1. The Rogel Cancer Center, Department of Internal Medicine, Department of Pharmacology, and Department of Medicinal Chemistry, University of Michigan, Ann Arbor, Michigan 48109, United States

2. Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48109, United States

Funder

National Cancer Institute

Oncopia Therapeutics, Inc.

Proteovant Therapeutics, Inc.

Publisher

American Chemical Society (ACS)

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.3c02124

Reference64 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Androgen receptor signaling in prostate cancer development and progression